Supplies of some hormone replacement therapies will be resupplied earlier than expected, following a decision to fast-track their manufacture.
Pharmacy Research UK and Diabetes UK have joined forces to provide funding for research exploring the role of pharmacy in diabetes care.
The Liberal Democrats have said their policy is to give pharmacists write access to patient’s medical records in advance of the general election, on 12 December 2019.
Almost half of pharmacists who responded to a survey on workforce wellbeing said they worry about making mistakes or providing a poor-quality service to their patients.
The proportion of pharmacists working in primary care has increased by five percentage points in the past six years, according to a survey by the General Pharmaceutical Council.
MHRA considering 'further action' after metformin diabetes drugs recalled in Singapore over impurities
The Medicines and Healthcare products Regulatory Agency is considering whether to take “further action” after metformin products were recalled in Singapore over reports of contamination.
Switching patients who use metered-dose inhalers, which contain hydrofluoroalkane propellants, to cheaper, more environmentally friendly alternatives could lead to major cost savings, as well as reduced NHS greenhouse gas emissions.
Benzodiazepines and Z-drugs are prescribed more frequently in areas of greater socioeconomic deprivation, a study published in Family Practice has shown.
There is a lack of high-quality evidence supporting the use of cannabinoids in the treatment of mental disorders, the authors of a meta-analysis published in the Lancet Psychiatry have concluded.
Having a flu vaccination during pregnancy helps to prevent infection and admission to hospital in babies, a study funded by Public Health England has found.
Use of antidepressants among older people has more than doubled over the past 20 years, despite little change in the prevalence of depression, research published in The British Journal of Psychiatry has shown.
Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.